baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UBS Knock-Out AMGN/ DE000UM2B9D9 /

10/07/2024 10:01:05	Chg.-0.020	Bid10:01:05	Ask10:01:05	Underlying	Strike price	Expiration date	Option type
0.550EUR	-3.51%	0.550 Bid Size: 50,000	0.590 Ask Size: 50,000	Amgen Inc	377.016 USD	31/12/2078	Put

GlobeNewswire 01/07 Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer

GlobeNewswire 27/06 Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 M...

GlobeNewswire 27/06 Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All ...

GlobeNewswire 26/06 COUR Pharmaceuticals Appoints Tim Walbert to its Board of Directors

GlobeNewswire 26/06 Compass Pathways appoints Lori Englebert as Chief Commercial Officer

GlobeNewswire 25/06 Arthritis Foundation Launches Carolina Hills Classic Bike Tour, Coming June 2025

TeleTrader 24/06 US closes mostly lower, as energy, banking stocks take lead

GlobeNewswire 20/06 Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7...

GlobeNewswire 19/06 Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

GlobeNewswire 18/06 CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Confere...

GlobeNewswire 17/06 CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

GlobeNewswire 17/06 FDA Approves Phase II Clinical Trial for Ruxoprubart in ANCA Associated Vasculitis (AAV) – a Chronic...

GlobeNewswire 17/06 Solid Power Appoints Renewables Industry Veteran Linda Heller as Chief Financial Officer

GlobeNewswire 05/06 Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

GlobeNewswire 30/05 Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affa...

TeleTrader 28/05 US markets turn to losses, Dow plunges 330 points

TeleTrader 28/05 Wall Street opens mostly higher as T+1 stock trading returns

GlobeNewswire 28/05 Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

GlobeNewswire 27/05 Samsung Bioepis Announces Oral Presentation on Switching Period Results for SB16, a Proposed Biosimi...

GlobeNewswire 23/05 Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...

GlobeNewswire 22/05 CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire 22/05 Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...

GlobeNewswire 21/05 Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

GlobeNewswire 21/05 Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a bios...

GlobeNewswire 21/05 COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer

UBS Knock-Out AMGN/ DE000UM2B9D9 /

If you wish to receive reply to your feedback, please provide your email address.